Affiliation:
1. Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
Abstract
Background:
Non-alcoholic fatty liver disease (NAFLD) and its advanced form non-alcoholic steatohepatitis
(NASH) are the most common causes of elevated liver enzymes in the general population. NASH, and to a
lesser extent NAFLD have been associated with increased liver-related, cardiovascular disease (CVD), and allcause
mortality. No effective treatment is widely acceptable.
Objective:
The purpose of this review is to summarize available data on the impact of statins on NAFLD and
NASH.
Method:
A comprehensive review of the literature was performed to identify studies assessing the effect of statin
use in NAFLD/NASH.
Results:
Recent reports have shown that the use of statins in patients with elevated plasma aminotransferases may
be beneficial. Post hoc data from three large prospective randomized clinical trials (n>11, 000) suggest that specific
statins (mainly atorvastatin) ameliorate NAFLD/NASH and reduce CVD events twice as much as in those with
normal liver function. Several biopsy studies have found that rosuvastatin use is related with significant histological
ameliorating effects in the setting of NASH. Statin treatment may also protect from hepatocellular carcinoma
(HCC) related to NAFLD/NASH.
Conclusion:
Since NAFLD/NASH patients have high CVD risk, they will probably require a statin. Thus, why not
select a specific statins (atorvastatin or rosuvastatin, both generic now) that offer a substantial liver- and CVDrelated
adverse event reduction? The administration of statins in these patients is as safe as in the general population.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献